Derma Sciences (DSCI) Tops Q1 EPS by 6c; Outlook Affirmed

Derma Sciences (NASDAQ: DSCI) reported Q1 EPS of ($0.07), $0.06 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.2 million versus the consensus estimate of $20.6 million.

Derma Sciences reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Derma Sciences (DSCI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c